Sonus shares surge as FDA approves Phase III design
Shares of Bothell, Washington-based Sonus Pharmaceuticals surged after the biotech announced that the FDA had approved its design for a Phase III trial of an experimental breast cancer therapy. The study will compare its Tocosol Paclitaxel against Taxol. Before the trial gets fully underway, though, Sonus needs to raise cash for the study.
"Our corporate development efforts are now focused on securing the necessary financial resources to support the study, and these efforts are ongoing on several fronts," said Michael A. Martino, President and CEO of Sonus. "In parallel, we have already begun to study start-up activities for the Phase 3 trial."
- read this press release for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
